semaglutide bone loss New studies have raised fresh alarms about the popular “weight-loss drug” Ozempic, revealing it may accelerate and weaken skeletal health in users. Research published in 2025–2026 shows patients on Research is raising questions about

Lilly USA LLC is the only United States company with FDA-approved products containing tirzepatide identified under the trade names Zepbound and Mounjaro Results based on a January 2026 analysis of 14,203 Noom GLP-1Rx Program members who actively logged weight over a 40-week period

Supplementation with 2,000 to 4,000 IU daily corrects deficiency in most individuals within eight to twelve weeks

Inconsistency: GHK-Cu works best with consistent, daily use over months

The upfront costs of GLP-1s are an ongoing concern for both public and private payers, and some employers and state Medicaid programs are now restricting coverage, despite recognizing their effectiveness at treating obesity